ISGlobal, Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK Building), 08036, Barcelona, Catalonia, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Malar J. 2018 Jun 1;17(1):219. doi: 10.1186/s12936-018-2369-3.
The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly available WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls were examined with seven in-house qSAT multiplex assays measuring IgG, IgG subclasses, IgM and IgE against a panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions.
Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude of IgG and IgG responses were highest when the WHO reference reagent was incubated with antigen-coupled beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h and 4 °C overnight, indicating no difference in unspecific binding.
With this study, the immunogenicity profile of the WHO reference reagent, including seven immunoglobulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for antibody measurements against the antigens tested. Although the WHO reference reagent performed well to measure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) and isotypes/subclasses (e.g. IgM) under study.
定量悬浮阵列技术(qSAT)是发现疟疾免疫标志物的有用平台。然而,对于大型血清流行病学和疟疾疫苗研究来说,一个主要的挑战是实验室之间的可比性,这需要获得标准化的对照试剂来优化检测,监测性能并提高重现性。在这里,使用七种内部 qSAT 多重分析试剂盒,检测了新获得的世界卫生组织(WHO)抗疟人类血浆参考试剂(10/198)和另外定制的阳性对照品对 40 种抗原的 IgG、IgG 亚类、IgM 和 IgE 的反应性。在不同的孵育时间和温度(4°C 过夜、37°C 2 小时、室温 1 小时)下测试不同的阳性对照品,以选择最佳条件。
总体而言,WHO 参考试剂的 IgG2、IgG4、IgM 和 IgE 水平较低,CSP 抗体水平也较低,因此该试剂富含 RTS,S 疫苗接种志愿者的血浆,用作 CSP 疫苗研究的标准。对于 IgM 分析,使用来自疟疾初次感染者的样本制备的另一种定制血浆池,该样本具有足够的 IgM 水平,证明作为阳性对照更为合适。当 WHO 参考试剂与抗原偶联珠在 4°C 孵育过夜时,IgG 和 IgG 反应的范围和幅度最高。在 37°C 孵育 2 小时和 4°C 孵育过夜之间,阴性对照中测量的 IgG 水平没有变化,表明非特异性结合没有差异。
通过这项研究,更好地描述了 WHO 参考试剂的免疫原性特征,包括七种免疫球蛋白同种型和亚类,以及更多的疟原虫抗原,包括领先的 RTS,S 疟疾疫苗中的抗原。总体而言,对于针对所测试抗原的抗体测量,样品在 4°C 孵育过夜的性能最佳。尽管 WHO 参考试剂在测量大多数常见的疟原虫血期抗原的 IgG 方面表现良好,但根据研究的抗原(例如低天然免疫原性的红细胞前蛋白)和同种型/亚类(例如 IgM),可能需要使用定制的池作为阳性对照。